EpiCast Report: Dyslipidemia – Epidemiology Forecast to 2025

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Dyslipidemia is a condition in which one or more of the serum lipid levels are abnormal. It is a well-established risk factor for cardiovascular disease (CVD), and the burden of morbidity, mortality, and medical costs arising from dyslipidemia is substantial

The clinical diagnostic criteria for dyslipidemia and serum lipid abnormalities vary across countries and depend on the disease treatment and management guidelines that are followed in each country. Guidelines for the detection, evaluation, treatment, and management of dyslipidemia, as well as the prevention of associated CVD, are updated periodically, which has led to further differences over the past several decades in how the prevalence of dyslipidemia is assessed in different studies. For this analysis, GlobalData epidemiologists estimated the total prevalent cases of serum lipid abnormalities according to country-specific cut-offs.

In 2015, there were 580,825,262 total prevalent cases of dyslipidemia in the 8MM. This is forecast to grow to 680,288,645 by 2025, at an Annual Growth Rate (AGR) of 1.71%. Urban China made up the majority of the total prevalent cases in the 8MM throughout the forecast period, and will also experience the highest growth from 274,741,284 total prevalent cases of dyslipidemia in 2015 to 348,184,445 cases by 2025, at an AGR of 2.67%. The US is forecast to grow at an AGR of 1.34%, from 133,104,335 total prevalent cases of dyslipidemia in 2015 to 150,918,348 cases by 2025. In the 8MM, there were 317,925,626 diagnosed prevalent cases of dyslipidemia, which is forecast to grow to 370,440,489 by 2025.

GlobalData epidemiologists used comprehensive, country-specific data from population-based national health surveys, such as the NHANES in the US and the CHNS in urban China. Additionally, data from peer-reviewed journal articles were utilized to arrive at a meaningful, in-depth analysis and forecast for the total prevalent cases of dyslipidemia, as well as other therapeutically significant patient populations including the diagnosed prevalent cases of dyslipidemia and the total prevalent cases of FH.

Scope

The Dyslipidemia EpiCast Report and EpiCast Model provides an overview of the risk factors, comorbidities, and global trends for dyslipidemia in the eight major markets (8MM) (US, France, Germany, Italy, Spain, UK, Japan, and China [urban]). It includes a 10-year epidemiological forecast for the total and diagnosed prevalent cases of dyslipidemia—which are defined as elevated low-density lipoprotein cholesterol (LDL-C), high triglycerides (TG), or low levels of high-density lipoprotein cholesterol (HDL-C)—as well as the total prevalent cases of increased LDL-C, and very high TG, segmented by sex and age. Additionally, the forecast provides the total prevalent cases of familial hypercholesterolemia (FH) and very high TG in these markets.

The dyslipidemia epidemiology report and model were written and developed by Masters- and PhD-level epidemiologists.

The EpiCast Report is in-depth, high quality, transparent and market-driven, providing expert analysis of disease trends in the 8MM.

The EpiCast Model is easy to navigate, interactive with dashboards, and epidemiology-based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over a 10-year forecast period using reputable sources.

Table of Contents

1Table of Contents

1.1List of Tables

1.2List of Figures

2Epidemiology

2.1Disease Background

2.2Risk Factors and Comorbidities

2.3Global Trends

2.4Forecast Methodology

2.4.1Sources Used Tables

2.4.2Forecast Assumptions and Methods

2.4.3Sources Not Used

2.5Epidemiological Forecast for Dyslipidemia (2015–2025)

2.5.1Dyslipidemia

2.5.2Familial Hypercholesterolemia

2.5.3Increased Low-Density Lipoprotein Cholesterol

2.5.4High Triglycerides

2.5.5Very High Triglycerides

2.5.6Low High-Density Lipoprotein Cholesterol

2.6Discussion

2.6.1Epidemiological Forecast Insight

2.6.2Limitations of the Analysis

2.6.3Strengths of the Analysis

3Appendix

3.1Bibliography

3.2About the Authors

3.2.1Epidemiologists

3.2.2Reviewers

3.2.3Global Director of Therapy Analysis and Epidemiology

3.3About GlobalData

3.4About EpiCast

3.5Disclaimer

Table

Table 1: Risk Factors and Comorbidities for Dyslipidemia

Table 2: 8MM, Sources Used to Forecast the Diagnosed Prevalent Cases of Dyslipidemia

Table 3: 8MM, Sources Used to Forecast the Total Prevalent Cases of FH

Table 4: 8MM, Sources Used to Forecast the Total Prevalent Cases of Increased LDL-C

Table 5: 8MM, Sources Used to Forecast the Total Prevalent Cases of High TG

Table 6: 8MM, Sources Used to Forecast the Total Prevalent Cases of Low HDL-C

Table 7: 8MM, Total Prevalent Cases of Dyslipidemia, Ages =20 Years, Both Sexes, N, Selected Years 2015–2025

Table 8: 8MM, Diagnosed Prevalent Cases of Dyslipidemia, Ages =20 Years, Both Sexes, N, Selected Years 2015–2025

Table 9: 8MM, Total Prevalent Cases of Increased LDL-C, Ages =20 Years, Both Sexes, N, Selected Years, 2015–2025

Table 10: 8MM, Total Prevalent Cases of High TG, Ages =20 Years, Both Sexes, N, Selected Years, 2015–2025

Table 11: 8MM, Total Prevalent Cases of Very High TG, Ages =20 Years, Both Sexes, N, Selected Years, 2015–2025

Table 12: 8MM, Total Prevalent Cases of Low HDL-C, Ages =20 Years, Both Sexes, N, Selected Years 2015–2025

Figures

Figure 1: 8MM Total Prevalent Cases of Dyslipidemia, Ages =20 Years, Both Sexes, N, 2015–2025

Figure 2: 8MM Diagnosed Prevalent Cases of Dyslipidemia, Ages =20 Years, Both Sexes, N, 2015–2025

Figure 3: 8MM, Total Prevalent Cases of FH, Both Sexes, Ages =20 Years, N, 2015 and 2025

Figure 4: 8MM, Total Prevalent Cases of Increased LDL-C, Both Sexes, Ages =20 Years, N, 2015 and 2025

Figure 5: 8MM, Sex-Specific Total Prevalent Cases of Increased LDL-C, Both Sexes, Ages =20 Years, N, 2015

Figure 6: 8MM, Age-Specific Total Prevalent Cases of Increased LDL-C, Both Sexes, Ages =20 Years, 2015

Figure 7: 8MM, Age-Standardized Total Prevalence of Increased LDL-C, Both Sexes, Ages =20 Years, 2015

Figure 8: 8MM, Total Prevalent Cases of High TG, Both Sexes, Ages =20 Years, N, 2015–2025

Figure 9: 8MM, Sex-Specific Total Prevalent Cases of High TG, Both Sexes, Ages =20 Years, N, 2015

Figure 10: 8MM, Age-Specific Total Prevalent Cases of High TG, Both Sexes, Ages =20 Years, 2015

Figure 11: 8MM, Age-Standardized Total Prevalence of High TG, Both Sexes, Ages =20 Years, 2015

Figure 12: 8MM, Total Prevalent Cases of Very High TG, Both Sexes, Ages =20 Years, N, 2015–2025

Figure 13: 8MM, Total Prevalent Cases of Low HDL-C, Both Sexes, Ages =20 Years, N, 2015–2025

Figure 14: 8MM, Sex-Specific Total Prevalent Cases of Low HDL-C, Ages =20 Years, N, 2015

Figure 15: 8MM, Age-Specific Total Prevalent Cases of Low HDL-C, Both Sexes, Ages =20 Years, 2015

Figure 16: 8MM, Age-Standardized Total Prevalence of Low HDL-C, Both Sexes, Ages =20 Years, 2015

Frequently asked questions

EpiCast Report: Dyslipidemia – Epidemiology Forecast to 2025 standard reports
Currency USD
$3,995

Can be used by individual purchaser only

$11,985

Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company


Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts

reportstore@globaldata.com
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

EpiCast Report: Dyslipidemia – Epidemiology Forecast to 2025 was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at EpiCast Report: Dyslipidemia – Epidemiology Forecast to 2025 in real time.

  • Access a live EpiCast Report: Dyslipidemia – Epidemiology Forecast to 2025 dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.